VVUS

Vivus, Inc. (Nasdaq: VVUS) is a U.S.-based biopharmaceutical company that develops and commercializes prescription medicines, with a primary focus on obesity and related metabolic disorders. The company markets Qsymia, a combination drug for weight management, and maintains a pipeline of obesity-oriented therapies.

Qsymia, the brand name for phentermine/topiramate extended-release, received approval from the U.S. Food and Drug Administration in 2012 for chronic weight management in adults. It combines a sympathomimetic agent (phentermine) with the anticonvulsant topiramate. The product is intended for adults who are overweight or obese when used in conjunction with diet and exercise, and it is subject to a REMS due to safety concerns including fetal risk. Physicians prescribing Qsymia implement the REMS program to ensure safe use, particularly to minimize exposure during pregnancy.

In addition to Qsymia, Vivus has pursued other obesity-related product candidates and strategic partnerships intended to broaden its portfolio. The company operates in a competitive landscape for anti-obesity therapies, with other approved drugs and various pipeline programs in the sector.

Headquartered in California, Vivus trades publicly on the Nasdaq stock market under the ticker VVUS. The company has positioned itself as a specialty pharmaceutical company focused on obesity and metabolic disease areas, aiming to advance therapies through development, regulatory approvals, and commercialization.